title: Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events.
abstract: Blood lipids and high-sensitivity C-reactive protein (hs-CRP) are altered by hormone therapy. The goal of the present study was to determine whether lipids and hs-CRP have predictive value for hormone therapy benefit or risk for coronary heart disease events in postmenopausal women without previous cardiovascular disease. A nested case-control study was performed in the Women's Health Initiative hormone trials. Baseline lipids and hs-CRP were obtained from 271 incident patients with coronary heart disease (cases) and 707 controls. In a combined trial analysis, favorable lipid status at baseline tended to predict better coronary heart disease outcomes when using conjugated equine estrogen (CEE) with or without medroxyprogesterone acetate (MPA). Women with a low-density lipoprotein (LDL)/high-density lipoprotein (HDL) cholesterol ratio <2.5 had no increase in risk of coronary heart disease when using CEE with or without MPA (odds ratio 0.60, 95% confidence interval 0.34 to 1.06), whereas women with an LDL/HDL cholesterol ratio > or =2.5 had increased risk of coronary heart disease (odds ratio 1.73, 95% confidence interval 1.18 to 2.53, p for interaction = 0.02). Low hs-CRP added marginally to the value of LDL/HDL ratio <2.5 when predicting coronary heart disease benefit on hormone therapy. In conclusion, postmenopausal women with undesirable lipid levels had excess coronary heart disease risk when using CEE with or without MPA. However, women with favorable lipid levels, especially LDL/HDL cholesterol ratio <2.5, did not have increased risk of coronary heart disease with CEE with or without MPA irrespective of hs-CRP.
authors.affiliation: Cardeza Foundation for Hematologic Research and Jefferson Medical College, Philadelphia, Pennsylvania, USA. paul.bray@jefferson.edu
authors.forename: Paul F
authors.initials: PF
authors.lastname: Bray
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Larson
authors.forename: Andrea Z
authors.initials: AZ
authors.lastname: Lacroix
authors.forename: Joann
authors.initials: J
authors.lastname: Manson
authors.forename: Marian C
authors.initials: MC
authors.lastname: Limacher
authors.forename: Jacques E
authors.initials: JE
authors.lastname: Rossouw
authors.forename: Norman L
authors.initials: NL
authors.lastname: Lasser
authors.forename: William E
authors.initials: WE
authors.lastname: Lawson
authors.forename: Marcia L
authors.initials: ML
authors.lastname: Stefanick
authors.forename: Robert D
authors.initials: RD
authors.lastname: Langer
authors.forename: Karen L
authors.initials: KL
authors.lastname: Margolis
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D003327:Coronary Disease / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D004967:Estrogens / Q000009:adverse effects* / Q000627:therapeutic use; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000097:blood*; D008593:Menopause / Q000097:blood* / Q000187:drug effects; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D008055:Lipids; D002097:C-Reactive Protein